RecruitingPhase 1Phase 2NCT02215889

Partial Liver Segment 2/3 Transplantation Study

A Phase I/II Clinical Trial to Evaluate the Benefit and Efficacy of Liver Resection And Partial Liver Segment 2/3 Transplantation With Delayed Total Hepatectomy as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma

Sponsor

Oslo University Hospital

Enrollment

20 participants

Start Date

Jun 1, 2014

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer

Summary

The patients will receive hepatectomy as a 2 stage procedure. In the first surgical procedure liver segments 2-3 are removed and liver donor segments 2-3 inserted. After growth of donor segments 2-3, the remaining liver segments of the recipient are removed. The patient will at this time have only donor liver tissue in place.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether a partial liver transplant can help patients with colorectal cancer that has spread only to the liver and cannot be removed with standard surgery, offering a potentially curative option that is not normally considered for these patients. **You may be eligible if...** - You have confirmed colorectal cancer (colon or rectal) that has spread to the liver, and the liver metastases cannot be surgically removed - There is no sign the cancer has spread outside the liver (you may have up to 3 small lung spots that are treatable) - Your general health is good (ECOG 0 or 1) - You have received at least 8 weeks of chemotherapy - Your blood levels (including hemoglobin, bilirubin, kidney function) are adequate **You may NOT be eligible if...** - You have lost more than 10% of your body weight in the last 6 months - Your BMI is over 30 - The cancer has spread to your bones or brain - You have previously had another cancer - Your organ function does not meet the minimum requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.